Specialty medical injectable drug program, requirements and drug policy updates

Review the following tables to determine changes to our specialty medical injectable drug programs.

SPECIALTY MEDICAL INJECTABLE DRUGS ADDED TO REVIEW AT LAUNCH

Drug Name UnitedHealthcare Commercial Treatment Uses

Elfabrio®

(pegunigalsidase alfa-iwxj)

X For the treatment of adults with Fabry disease.

QalsodyTM

(tofersen)

X For the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.

Review the UnitedHealthcare Commercial Plan Review at Launch Medication List.

For questions, please contact your broker or UnitedHealthcare representative.

More updates for your clients

New releases, updates and notifications for a broad spectrum of UnitedHealthcare products and services.

Important, required notices for products, plans, forms and more.

Need-to-know operational announcements for you and your clients.